Skip to main content
. 2023 Mar 16;16:22. doi: 10.1186/s13045-023-01409-5

Fig. 2.

Fig. 2

The evolving treatment landscape of B-ALL. Abbreviations: FL, frontline; InO, inotuzumab ozogamicin; MRD, measurable residual disease; Ph, Philadelphia chromosome; R/R, relapsed/refractory; SOC, standard of care